Advisory Board

Dr. Kristen Fortney

Kristen Fortney, Ph.D. is CEO at BioAge Labs.
BioAge Labs couples genomic data with machine learning to measure human aging and accelerate drug discovery.
Kristen’s papers include Network-based characterization of drug-regulated genes, drug targets, and toxicity, Inferring the functions of longevity genes with modular subnetwork biomarkers of Caenorhabditis elegans aging, Genome-wide scan informed by age-related disease identifies loci for exceptional human longevity, Integrative computational biology for cancer research, Whole-genome sequencing of the world’s oldest people, Visual data mining of biological networks: one size does not fit all, Resistance to genotoxic stresses in Arctica islandica, the longest living noncolonial animal: is extreme longevity associated with a multistress resistance phenotype?, and NetwoRx: connecting drugs to networks and phenotypes in Saccharomyces cerevisiae.
Kristen earned her Ph.D. in Medical Biophysics from the University of Toronto in 2012, and completed her postdoctoral training at Stanford University, where she was a postdoctoral fellow of the Ellison Medical Foundation / American Federation for Aging Research. She is an expert at developing novel bioinformatics approaches that harness large amounts of data to shed light on mechanisms of aging and age-related disease. Her research has focused on computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.
Watch Kristen Fortney at Health Extension Salon #2. Read A Search for Anti-Aging Secrets Starts With the Blood of 600 Estonians and BioAge Labs Raises $10.9M in Series A Financing. Read her Crunchbase profile, Google Scholar profile, and LinkedIn profile. Follow her Twitter feed.